PLX Protalix BioTherapeutics Inc

Price (delayed)

$1.16

Market cap

$85.05M

P/E Ratio

11.6

Dividend/share

N/A

EPS

$0.1

Enterprise value

$84.21M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
PLX's price to earnings (P/E) is 23% less than its last 4 quarters average of 14.8
PLX's debt is down by 21% YoY
PLX's net income has soared by 143% year-on-year but it is down by 18% since the previous quarter
PLX's EPS has surged by 133% year-on-year but it is down by 17% since the previous quarter
Protalix BioTherapeutics's quick ratio has decreased by 13% QoQ and by 13% YoY
Protalix BioTherapeutics's equity has decreased by 11% QoQ

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
73.32M
Market cap
$85.05M
Enterprise value
$84.21M
Valuations
Price to earnings (P/E)
11.6
Price to book (P/B)
2.84
Price to sales (P/S)
1.42
EV/EBIT
10.01
EV/EBITDA
8.73
EV/Sales
1.41
Earnings
Revenue
$59.65M
EBIT
$8.41M
EBITDA
$9.65M
Free cash flow
$4.37M
Per share
EPS
$0.1
Free cash flow per share
$0.06
Book value per share
$0.41
Revenue per share
$0.82
TBVPS
$1.23
Balance sheet
Total assets
$89.83M
Total liabilities
$60.04M
Debt
$26.37M
Equity
$29.79M
Working capital
$20.58M
Liquidity
Debt to equity
0.89
Current ratio
1.38
Quick ratio
0.95
Net debt/EBITDA
-0.09
Margins
EBITDA margin
16.2%
Gross margin
62.3%
Net margin
11.5%
Operating margin
13.5%
Efficiency
Return on assets
7.8%
Return on equity
19.5%
Return on invested capital
20%
Return on capital employed
24%
Return on sales
14.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
1.75%
1 week
9.43%
1 month
1.75%
1 year
-35.2%
YTD
-34.83%
QTD
-0.85%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$59.65M
Gross profit
$37.16M
Operating income
$8.06M
Net income
$6.85M
Gross margin
62.3%
Net margin
11.5%
Protalix BioTherapeutics's operating income has surged by 159% YoY but it has decreased by 23% QoQ
PLX's net income has soared by 143% year-on-year but it is down by 18% since the previous quarter
The operating margin has soared by 141% YoY but it has decreased by 16% from the previous quarter
PLX's net margin has soared by 130% YoY but it is down by 9% from the previous quarter

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
11.6
P/B
2.84
P/S
1.42
EV/EBIT
10.01
EV/EBITDA
8.73
EV/Sales
1.41
PLX's EPS has surged by 133% year-on-year but it is down by 17% since the previous quarter
PLX's price to earnings (P/E) is 23% less than its last 4 quarters average of 14.8
PLX's P/B is 18% below its last 4 quarters average of 3.4
Protalix BioTherapeutics's equity has decreased by 11% QoQ
Protalix BioTherapeutics's revenue has increased by 45% YoY but it has decreased by 9% from the previous quarter
PLX's price to sales (P/S) is 22% lower than its last 4 quarters average of 1.8 and 13% lower than its 5-year quarterly average of 1.6

Efficiency

How efficient is Protalix BioTherapeutics business performance
The return on invested capital has surged by 163% year-on-year but it has declined by 19% since the previous quarter
PLX's return on sales has surged by 143% year-on-year but it is down by 12% since the previous quarter
The ROA has soared by 130% YoY but it has contracted by 24% from the previous quarter
Protalix BioTherapeutics's return on equity has decreased by 34% QoQ

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 50% greater than its total liabilities
PLX's total assets is up by 35% year-on-year and by 6% since the previous quarter
The company's current ratio fell by 22% YoY and by 10% QoQ
PLX's debt is 11% less than its equity
The debt to equity has dropped by 97% year-on-year but it is up by 14% since the previous quarter
PLX's debt is down by 21% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.